Teligene Ltd

China’s top securities regulator has confirmed a recent slowdown in the review of initial public offering applications to help stabilize the domestic stock market, making the go-public process for Chi

Two innovative drug-focused Chinese bioventures are trying their luck with public share sales on China’s Nasdaq-like STAR Market under the Shanghai Stock Exchange, ending a more than six-month break i